Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PPOX | P50336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27655269 | 0.81 | PDE4A (0.42) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL24696478 | 0.78 | FEN1 (0.33) | CSNK2A1SCN9AMCHR1SCDHTR1A | |
| SCHEMBL30892367 | 0.78 | FEN1 (0.33) | CSNK2A1SCN9AMCHR1SCDHTR1A | |
| SCHEMBL26814565 | 0.74 | SCN9A (0.46) | SCN9APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15534488 | 0.74 | MCHR1 (0.42) | CSNK2A1MCHR1SCDCARM1PRMT1 | |
| SCHEMBL10188238 | 0.74 | CSNK2A1 (0.41) | CSNK2A1MCHR1FURINHTR1ASLC6A2 | |
| SCHEMBL1135987 | 0.74 | CSNK2A1 (0.44) | CSNK2A1MCHR1PDE4DPDE4BPDE4A | |
| SCHEMBL30612831 | 0.74 | CSNK2A1 (0.41) | CSNK2A1MCHR1FURINHTR1ASLC6A2 | |
| SCHEMBL19175421 | 0.74 | TRPV4 (0.37) | CSNK2A1 | |
| SCHEMBL2904851 | 0.74 | PDE4A (0.46) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-3601229-B1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD (GB) | 2024-11-06 | — | — | EP | disclosed |
| CN-110891938-B | Tetrahydro-benzo [ D ] azepine derivatives as GPR120 modulators | 卡尔丹治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | CALDAN THERAPEUTICS LTD (GB) | 2022-01-11 | — | — | US | disclosed |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-05-30 | — | — | US | disclosed |
| EP-3463362-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205193-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | CSNK2A1 1650/4885SCN9A 3912/4885MCHR1 497/4885 |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | CSNK2A1 1758/4885SCN9A 3752/4885MCHR1 442/4885 |
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | GPR119, GPR84, GPR65 | CSNK2A1 1267/4885SCN9A 2113/4885MCHR1 411/4885 |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | CSNK2A1 1758/4885SCN9A 3752/4885MCHR1 442/4885 |
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | GPR119, GPR84, GPR65 | CSNK2A1 1420/4885SCN9A 2030/4885MCHR1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.